Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 17380112)

Published in J Invest Dermatol on March 22, 2007


Pedro Redondo1, Julio del Olmo, Ascensión López-Diaz de Cerio, Susana Inoges, Miren Marquina, Ignacio Melero, Maurizio Bendandi

Author Affiliations

1: Department of Dermatology, University Clinic of Navarra, Pamplona, Navarra, Spain.

Associated clinical trials:

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | NCT03792724

Articles citing this

More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res (2011) 1.47

New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15

Nanoparticle preconditioning for enhanced thermal therapies in cancer. Nanomedicine (Lond) (2011) 1.03

Cryosurgery for lung cancer. J Thorac Dis (2012) 0.95

Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One (2013) 0.89

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol (2011) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med (2009) 0.82

Adjuvant approaches to enhance cryosurgery. J Biomech Eng (2009) 0.82

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract (2016) 0.75

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother (2016) 0.75

Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model. J Oncol (2012) 0.75

Articles by these authors

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95

Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61

Imatinib mesylate in cutaneous melanoma. J Invest Dermatol (2004) 1.48

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol (2007) 1.35

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25

SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem (2006) 1.19

Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13

Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13

Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05

Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04

A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03

Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01

Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00

Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem (2008) 0.98

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther (2006) 0.98

CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids (2013) 0.98

Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97

Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 0.96

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res (2012) 0.94

Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer (2011) 0.92

Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther (2005) 0.91

An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris. Exp Dermatol (2009) 0.91

Interleukin-15 in gene therapy of cancer. Curr Gene Ther (2013) 0.91

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer (2007) 0.90

Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells. Ann Hematol (2008) 0.90

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 0.89

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol (2011) 0.89

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol (2012) 0.88

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica (2007) 0.87

Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clin Cancer Res (2009) 0.87

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy (2009) 0.87

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res (2003) 0.86

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol (2010) 0.86

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85

Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. J Invest Dermatol (2013) 0.85

Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica (2004) 0.85

Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol (2002) 0.85

T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol (2013) 0.84

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer (2010) 0.83

Prolonged idiotypic vaccination against follicular lymphoma. Leuk Lymphoma (2009) 0.83

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83

CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J (2012) 0.83

Cell tracking using multimodal imaging. Contrast Media Mol Imaging (2013) 0.83

Methyl-ALA-induced fluorescence in photodynamic diagnosis of basal cell carcinoma prior to Mohs micrographic surgery. Arch Dermatol (2008) 0.82

Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J Hepatol (2009) 0.82

Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One (2011) 0.82

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 0.82

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol (2004) 0.81

Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol (2007) 0.81

Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica (2003) 0.81

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med (2012) 0.80

Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol (2012) 0.80

Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp Hematol (2002) 0.80

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther (2007) 0.80

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One (2011) 0.79

Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res (2009) 0.79

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother (2010) 0.79

Better performance of CARs deprived of the PD-1 brake. Clin Cancer Res (2013) 0.79

Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genet Cytogenet (2003) 0.78

Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res (2012) 0.78

Awareness and understanding of cancer immunotherapy in Europe. Hum Vaccin Immunother (2014) 0.77

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther (2005) 0.77

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res (2006) 0.77

Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma (2004) 0.77

The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. Immunotherapy (2012) 0.77

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol (2002) 0.76

Biologic therapy of liver tumors. Surg Clin North Am (2004) 0.76

Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol (2011) 0.76

Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. Oncoimmunology (2012) 0.75

Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. Arch Immunol Ther Exp (Warsz) (2002) 0.75

MAGE antigens: therapeutic targets in hepatocellular carcinoma? J Hepatol (2004) 0.75

Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines (2011) 0.75